Public recall detail

Janssen COVID-19 Vaccine and the Risk of Thrombosis with Thrombocytopenia

medium
Recall Safety notice
Quick summary

Quick summary: Janssen COVID-19 Vaccine and the Risk of Thrombosis with Thrombocytopenia .

Recommended action

Recommended action: compare your product with the official notice and follow the instructions published by the official source.

Recall details

Quick summary: Janssen COVID-19 Vaccine and the Risk of Thrombosis with Thrombocytopenia .

Official details

Affected product details

Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.

Brand

Issue

Janssen COVID-19 Vaccine was authorized for use in Canada on March 5, 2021 in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Since the time of authorization, there have been very rare reports of thrombosis with thrombocytopenia following administration of Janssen COVID-19 Vaccine.

Additional official information
Background{}
Companies
Audiences

Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.

Starting...

Related recalls

Similar recalls and safety notices.

Loading related recalls...